[Hiring] Unapplied Cash Analyst @Sarah Cannon Research Institute

Role Description

Our Unapplied Cash Analyst position is responsible for all cash application functions within the finance department including reviewing and reconciling unapplied cash and will support general areas of operations as well as provide administrative and organizational support. This is a remote position within the US; relocation assistance and visa sponsorship are not available.

• Review and reconcile unapplied cash
• Work closely with sites to confirm visit activity
• Enter charges into the clinical trial management system (CTMS) if/when needed
• Application of receivables to Cash Receipts Log for all lines of business
• Transactional line-item cash posting into proprietary systems based on remittance detail provided by pharmaceutical companies
• Ensure accuracy of cash postings by contacting pharmaceutical companies to verify payment remittance details
• Review, interpret and discuss remittances from payers for data accuracy

Qualifications

• High School Diploma obtained, Associate's Degree highly preferred
• 1+ year work experience with basic financial operations including: debits/credits, reconciliation, invoice structures and payment lifecycles
• Intermediate to advanced MS Excel skills
• Understanding of how payments flow, how to match payments to invoices, and how unapplied cash affects financials
• Ability to investigate discrepancies, interpret remittances, and resolve unidentified cash
• Strong attention to detail, problem solving and clear communication skills

Benefits

• Comprehensive benefits to support physical, mental, and financial well-being
• Competitive compensation package determined by performance, experience, skills, equity, and geographical markets
• Potential for annual bonus or long-term incentive opportunities

Company Description

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S.

We care about the well-being of the patients and communities we serve, and that starts with caring for our people.